Journal of Clinical Immunology

, Volume 30, Issue 3, pp 426–434 | Cite as

Proteolytically Inactive Per a 10 Allergen of Periplaneta americana Modulates Th2 Response and Enhances IL-10 in Mouse Model

  • Deepsikha Srivastava
  • Amit Kumar Mehta
  • Naveen Arora
  • Shailendra Nath Gaur
  • Bhanu Pratap SinghEmail author



Purified allergens with reduced IgE reactivity are required to improve the safety and efficacy of allergen-specific immunotherapy (IT).


The present study investigates the efficacy of purified cockroach allergen immunotherapy with proteolytically active and inactive Per a 10 in allergic mouse model.


Balb/c mice were sensitized intraperitoneally with cockroach extract (CE) and purified allergen Per a 10 in separate groups. Mice were treated subcutaneously with phosphate-buffered saline (PBS), CE, active and inactive Per a 10 and challenged intranasally. Antigen specific IgE, IgG1 and IgG2a in serum and cytokines IL-4, IL-13, IFN-γ, IL-10, TGF-β in bronchoalveolar lavage (BAL) fluid and spleen culture supernatant (CS) were estimated by enzyme-linked immunosorbent assay. Lung histology was analyzed by hematoxylin and eosin staining.


IT with Per a 10 demonstrated significant reduction in IgE levels in serum, IL-4 levels in BAL fluid, CS, and eosinophilic infiltration in lungs than PBS-treated mice. This was associated with significantly increased IL-10 secretion in BAL fluid and CS. IT with Per a 10 effectively suppressed T-helper type 2 (Th2) response in mice sensitized with Per a 10 than CE group. Further, IT with inactive Per a 10 showed maximum reduction in systemic and airway inflammation and induced maximum IL-10 release in BAL fluid and CS than other antigens.


IT with Per a 10 effectively suppressed Th2 response and lung inflammation in Per a 10- or CE-sensitized mice. The beneficial effects of IT with inactive Per a 10 are more pronounced than active Per a 10.


Animal model allergen immunotherapy P. americana Per a 10 serine protease 



Specific Immunotherapy


Spleen culture supernatant


Ethylenediamine tetraceticacid


Aminoethyl benzenesulfonyl fluoride hydrochloride


Phenylmethylsulfonyl fluoride


N-Benzoyl arginine ethyl ester hydrochloride


Whole body cockroach extract




Sodium dodecyl sulfate


Phosphate-buffered saline


Enzyme-linked immunosorbent assay


Bronchoalveolar lavage



One of the authors (Deepsikha) received financial assistance from Council of Scientific and Industrial Research, New Delhi, India.


  1. 1.
    Tatfeng YM, Usuanlele MU, Orukpe A, Digban AK, Okodua M, Oviasogie F, et al. Mechanical transmission of pathogenic organisms: the role of cockroaches. J Vector Borne Dis. 2005;42:129–34.PubMedGoogle Scholar
  2. 2.
    Kang B, Vellody D, Homburger H, Yunginger JW. Cockroach cause of allergic asthma. Its specificity and immunologic profile. J Allergy Clin Immunol. 1979;63:80–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang Z, Zhang H, Yang H, Zhang L, Chen X, Zheng X, et al. Induction of T-helper type 2 cytokine release and up-regulated expression of protease-activated receptors on mast cells by recombinant American cockroach allergen Per a 7. Clin Exp Allergy. 2008;38:1160–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Sudha VT, Arora N, Sridhara S, Gaur SN, Singh BP. Biopotency and identification of allergenic proteins in Periplaneta americana extract for clinical applications. Biologicals. 2007;35:131–7.CrossRefGoogle Scholar
  5. 5.
    Bhat RK, Page K, Tan A, Hershenson MB. German cockroach extract increases bronchial epithelial cell interleukin-8 expression. Clin Exp Allergy. 2003;33:35–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Bateman ED, Jithoo A. Asthma and allergy—a global perspective. Allergy. 2007;62:213–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2:446–53.PubMedGoogle Scholar
  9. 9.
    Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy. 2004;59:74–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2006;118:1026–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969–74.PubMedGoogle Scholar
  12. 12.
    Barnes PJ. Is immunotherapy for asthma worthwhile? N Engl J Med. 1996;334:531–2.CrossRefPubMedGoogle Scholar
  13. 13.
    Valenta R, Twaroch T, Swoboda I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J Investig Allergol Clin Immunol. 2007;17:36–40.PubMedGoogle Scholar
  14. 14.
    Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy. 2004;34:597–603.CrossRefPubMedGoogle Scholar
  15. 15.
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558–62.CrossRefPubMedGoogle Scholar
  16. 16.
    Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 2002;16:414–6.PubMedGoogle Scholar
  17. 17.
    Kazemi-Shirazi L, Niederberger V, Linhart B, Lindholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol. 2002;127:259–68.CrossRefPubMedGoogle Scholar
  18. 18.
    Sudha VT, Arora N, Gaur SN, Pasha S, Singh BP. Identification of a serine protease as a major allergen (Per a 10) of Periplaneta americana. Allergy. 2008;63:768–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Sudha VT, Arora N, Singh BP. Serine protease activity of Per a 10 augments allergen-induced airway inflammation in a mouse model. Eur J Clin Invest. 2009;39:507–16.CrossRefPubMedGoogle Scholar
  20. 20.
    Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol. 2004;113:1204–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Mehta AK, Gaur SN, Arora N, Singh BP. Effect of choline chloride in allergen-induced mouse model of airway inflammation. Eur Respir J. 2007;30:662–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Chapman MD, Vailes LD, Hayden ML, Platts-Mills TAE, Arruda LK. Cockroach allergens and their role in asthma. In: Kay AB, editor. Allergy and allergic diseases. Oxford: Blackwell Science; 1996. p. 942–51.Google Scholar
  23. 23.
    Alonso A, Albonico JF, Mouchian K, Scavini LM, Iraneta SG, Pionetti CH. Immunological changes during cockroach immunotherapy. J Investig Allergol Clin Immunol. 1999;9:299–304.PubMedGoogle Scholar
  24. 24.
    Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. J Asthma. 1998;25:205–18.Google Scholar
  25. 25.
    Takabayashi K, Libet L, Chisholm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J Immunol. 2003;170:3898–905.PubMedGoogle Scholar
  26. 26.
    Janssen EM, van Oosterhout AJ, Nijkamp FP, van Eden W, Wauben MH. The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapy. J Immunol. 2000;165:7207–14.PubMedGoogle Scholar
  27. 27.
    Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy. 2007;37:488–97.CrossRefPubMedGoogle Scholar
  28. 28.
    Yu HQ, Liu ZG, Yu KY, Xu ZQ, Qiu J. Immunotherapy with recombinant house dust mite group 2 allergen vaccines inhibits allergic airway inflammation in mice. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2006;24:414–9.PubMedGoogle Scholar
  29. 29.
    Neimert-Andersson T, Thunberg S, Swedin L, Wiedermann U, Jacobsson-Ekman G, Dahlen SE, et al. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy. 2008;63:518–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Van Oosterhout AJ, Van Esch B, Hofman G, Hofstra CL, Van Ark I, Nijkamp FP, et al. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma. Am J Respir Cell Mol Biol. 1998;19:622–8.PubMedGoogle Scholar
  31. 31.
    Finkelman FD, Holmes J, Urban Jr JF, Paul WE, Katona IM. T help requirements for the generation of an in vivo IgE response: a late acting form of T cell help other than IL-4 is required for IgE but not for IgG1 production. J Immunol. 1989;142:403–8.PubMedGoogle Scholar
  32. 32.
    Gough L, Shulz O, Sewell HF, Shakib F. The cysteine protease activity of the major dust mite allergen Der p 1 selectively enhances the immunoglobulin E antibody response. J Exp Med. 1999;190:1897–902.CrossRefPubMedGoogle Scholar
  33. 33.
    Papouchado BG, Chapoval SP, Marietta EV, Weiler CR, David CS. Cockroach allergen-induced eosinophilic airway inflammation in HLA-DQ/human CD4 (+) transgenic mice. J Immunol. 2001;167:4627–34.PubMedGoogle Scholar
  34. 34.
    Finkelman FD, Katona IM, Urban Jr JF, Holmes J, Ohara J, Tung AS, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol. 1998;141:2335–41.Google Scholar
  35. 35.
    Ebner C, Siemann U, Bohle B. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative response to allergen and shift from Th2 to Th1 in T cell clones specific for Phl p I, a major grass pollen allergen. Clin Exp Allergy. 1997;27:1007–15.CrossRefPubMedGoogle Scholar
  36. 36.
    O’Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998;17:1006–18.CrossRefPubMedGoogle Scholar
  37. 37.
    Castro AG, Neighbors M, Hurst SD, Zonin F, Silva RA, Murphy E. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med. 2000;192:1529–34.CrossRefPubMedGoogle Scholar
  38. 38.
    Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102:98–106.CrossRefPubMedGoogle Scholar
  39. 39.
    Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205–14.CrossRefPubMedGoogle Scholar
  40. 40.
    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255–61.CrossRefPubMedGoogle Scholar
  41. 41.
    Mousavi T, Salek Moghadam A, Falak R. Immunotherapy of Chenopodium album induced asthma by intranasal administration of CpG oligodeoxynucleotides in BALB/c mice. Iran J Immunol. 2008;5:57–63.PubMedGoogle Scholar
  42. 42.
    Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237–40.CrossRefPubMedGoogle Scholar
  43. 43.
    Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996;183:2605–16.CrossRefPubMedGoogle Scholar
  44. 44.
    Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest. 2003;111:291–7.PubMedGoogle Scholar
  45. 45.
    Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol. 2007;120:278–85.CrossRefPubMedGoogle Scholar
  46. 46.
    Bousquet J, Becker WM, Hejjaoui A, Chanal I, Lebel B, Dhivert H, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. II. Efficacy of a doubleblind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol. 1991;88:43–53.CrossRefPubMedGoogle Scholar
  47. 47.
    Pene J, Rivier A, Lagier B, Becker WM, Michel FB, Bousquet J. Differences in IL-4 release by PBMC are related with heterogeneity of atopy. Immunology. 1994;81:58–64.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Deepsikha Srivastava
    • 1
    • 2
  • Amit Kumar Mehta
    • 1
    • 2
  • Naveen Arora
    • 1
  • Shailendra Nath Gaur
    • 3
  • Bhanu Pratap Singh
    • 1
    Email author
  1. 1.Allergy and Immunology Section, Institute of Genomics and Integrative Biology (CSIR)Delhi University CampusDelhiIndia
  2. 2.Department of BiotechnologyUniversity of PunePuneIndia
  3. 3.Department of Pulmonary Medicine, V. P. Chest InstituteUniversity of DelhiDelhiIndia

Personalised recommendations